Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5625197 | 0.85 | PDE2A (0.45) | GRM2TP53MEN1KMT2APKM | |
| SCHEMBL3057359 | 0.83 | PPARG (0.41) | PPARGTP53BRD4TSHRPDE10A | |
| SCHEMBL3059860 | 0.76 | CTSS (0.38) | GRM2TP53MEN1KMT2APKM | |
| SCHEMBL3060150 | 0.75 | TP53 (0.47) | GRM2TP53MEN1KMT2APKM | |
| SCHEMBL3065554 | 0.74 | RPS6KA5 (0.42) | GRM2MEN1KMT2APKMBRD4 | |
| SCHEMBL3057721 | 0.73 | S1PR1 (0.35) | GRM2TP53BRD4RPS6KA5 | |
| SCHEMBL3049980 | 0.72 | CYP3A4 (0.35) | TP53PKMBRD4CYP3A4RPS6KA5 | |
| SCHEMBL5630165 | 0.72 | AOC2 (0.42) | GRM2TP53BRD4RPS6KA5 | |
| SCHEMBL3055661 | 0.72 | PTGER4 (0.38) | TP53MEN1KMT2APKM | |
| SCHEMBL14368292 | 0.71 | RPS6KA5 (0.38) | GRM2TP53MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | PPARG 409/4885GRM2 217/4885TP53 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.